Robeco Institutional Asset Management B.V. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 1.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,261,425 shares of the biopharmaceutical company’s stock after selling 48,816 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.19% of Pfizer worth $109,555,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the 2nd quarter valued at $102,000. D. Scott Neal Inc. raised its holdings in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new position in Pfizer in the 2nd quarter worth $120,000. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer in the 1st quarter worth $121,000. Finally, Private Vista LLC raised its holdings in Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares in the last quarter. Institutional investors own 69.89% of the company’s stock.

Several research analysts have commented on the stock. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 10th. Barclays set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $38.66.

Pfizer Inc. (NYSE PFE) traded down $0.21 during trading hours on Tuesday, hitting $35.86. 5,396,030 shares of the stock were exchanged, compared to its average volume of 19,979,412. The stock has a market cap of $216,671.69, a P/E ratio of 14.54, a PEG ratio of 2.57 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 12-month low of $30.51 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 EPS. analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.57%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio is presently 79.01%.

In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Insiders sold a total of 60,280 shares of company stock worth $2,118,988 over the last ninety days. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Robeco Institutional Asset Management B.V. Sells 48,816 Shares of Pfizer Inc. (PFE)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/05/robeco-institutional-asset-management-b-v-sells-48816-shares-of-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.